Gilead Sciences, Inc. vs Nebius Group NV — how do they compare? Gilead Sciences, Inc. trades at $135.5 (market cap $168.35B), while Nebius Group NV trades at $218.09 (market cap $49.06B). The key difference: Gilead Sciences, Inc. is far larger — about 3.4× Nebius Group NV's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Nebius Group NV pays none. Which is the better fit depends on your goals.
| GILD | NBIS | |
|---|---|---|
Market Cap | $168.35B | $49.06B |
Sector | Health | Technology |
52-Week High | $155.80 | $286.69 |
52-Week Low | $110.56 | $64.06 |
Enterprise Value | $191.42B | $49.26B |
Dividend Yield | 2.42% | — |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →